1C
GILD icon

111 Capital’s Gilead Sciences GILD Stock Holding History

111 Capital’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2M Sell
15,807
-3,898
-20% -$514K 0.34% 57
2026
Q1 		$2.75M Buy
19,705
+2,581
+15% +$361K 0.68% 23
2025
Q4 		$2.1M Sell
17,124
-7,913
-32% -$962K 0.46% 35
2025
Q3 		$2.78M Buy
25,037
+2,129
+9% +$242K 0.53% 33
2025
Q2 		$2.54M Sell
22,908
-9,679
-30% -$1.03M 0.44% 42
2025
Q1 		$3.65M Buy
32,587
+21,811
+202% +$2.25M 0.7% 23
2024
Q4 		$995K Buy
+10,776
New +$970K 0.21% 99

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

111 Capital's GILD Position: Q2 2026 in Review

111 Capital reduced its Gilead Sciences (GILD) stake by 20% in Q2 2026, selling an estimated $514K and leaving 15,807 shares worth $2M. The position accounts for 0.34% of the portfolio, ranked #57.

111 Capital first reported a position in GILD in Q4 2024 and has held it in 7 quarters since. The position peaked at $3.65M in Q1 2025. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • 111 Capital held 15,807 shares of Gilead Sciences worth $2M as of Q2 2026.
  • 111 Capital sold 3,898 Gilead Sciences shares in Q2 2026, an estimated $514K.
  • Gilead Sciences made up 0.34% of 111 Capital's portfolio in Q2 2026, its #57 holding.
  • 111 Capital first reported a position in Gilead Sciences in Q4 2024 and has held it in 7 quarters since.
  • 111 Capital's Gilead Sciences position peaked at $3.65M in Q1 2025.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on 111 Capital's 13F filing for Q2 2026, filed 5 Aug 2026.